Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Xetra  >  Evonik Industries AG    EVK   DE000EVNK013


SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Evonik Industries AG: Evonik confirms full-year earnings outlook despite ongoing weakness in global economy

share with twitter share with LinkedIn share with facebook
11/05/2019 | 02:05am EDT

DGAP-News: Evonik Industries AG / Key word(s): 9 Month figures
Evonik Industries AG: Evonik confirms full-year earnings outlook despite ongoing weakness in global economy

05.11.2019 / 07:00
The issuer is solely responsible for the content of this announcement.

Key Financial Data: Third quarter 2019

Evonik confirms full-year earnings outlook despite ongoing weakness in global economy

- 2019: Adjusted EBITDA to remain at least stable

- Free cash flow outlook for full year confirmed and specified: around EUR700 million

- Q3: Sales and operating earnings below year-ago period

- Stricter cost discipline supports earnings

Essen, Germany. Evonik is sticking to its full-year earnings outlook despite an ongoing weakness in the global economy. The company expects adjusted EBITDA to remain at least stable compared with last year. Sales are now expected to be slightly lower than the previous year because of lower demand. Evonik had expected sales to remain stable. In 2018 Evonik generated - excluding the divested Methacrylates business - sales of
EUR13.3 billion and adjusted EBITDA of EUR2.15 billion.

"We prepared ourselves at an early stage with stricter cost discipline and additional contingency measures for a cooling global economy," said Christian Kullmann, chairman of Evonik's executive board. "We are being very proactive to ensure we meet our full-year outlook."

The 2018 initiated efficiency program to reduce administrative and selling expenses by EUR200 million annually has been accelerated. By end of this year, Evonik will achieve EUR120 million of savings, EUR20 million more than originally planned. A further EUR20 million will be saved with additional contingency measures such as delaying new hires and more restrictive expenditure on external services.

Evonik is specifying its full-year outlook for free cash flow and is now expecting a level of around EUR700 million, a significantly higher free cash flow compared with last year. This is mainly due to lower capex spending, less build-up of net working capital and the partial reimbursement of pension payments from the Contractual Trust Arrangement (CTA). The more precise outlook does not include taxes incurred from the carve out of the divested Methacrylates business.

The global economic slowdown continued to impact Evonik's performance in the third quarter. In the months July to September sales fell 3 percent to EUR3.23 billion due to lower volumes and selling prices. Adjusted EBITDA fell 6 percent year-on-year to EUR543 million.

Segment Performance

Resource Efficiency: Segment sales declined 1 percent to EUR1.4 billion in the third quarter. Coatings as well as the adhesive and resins business was affected by the global economic slowdown, especially in the automotive and coatings sector. Sales volumes declined for industry-related silica applications. In contrast, high-performance polymers benefited from solid demand for membranes and from the 3D printing industry. Crosslinkers saw high demand from the wind industry. Adjusted EBITDA dropped 4 percent to EUR322 million.

Nutrition & Care: Sales declined 2 percent to EUR1.14 billion in the third quarter. Demand for essential amino acids for animal nutrition remained high while selling prices declined further. In the Health Care business sales increased, especially due to good demand for pharma and food ingredients. Sales increased significantly for polyurethane-foam additives, mostly on high demand for durable consumer goods and insulation. Adjusted EBITDA at the segment dropped 11 percent to EUR188 million.

Performance Materials: Sales in the third quarter decreased 20 percent to EUR475 million compared with the prior-year quarter. Development at Performance Intermediates was impaired by a lower oil and naphtha price and slightly lower selling prices. Continuing constraints in raw-material supply and technical problems at the C4 plants in Marl and Antwerp weighed on earnings. At Functional Solutions the alkoxides business developed well. Adjusted EBITDA declined 25 percent to EUR47 million at the segment.


Company information
Evonik is one of the world leaders in specialty chemicals. The focus on more specialty businesses, customer-oriented innovative prowess and a trustful and performance-oriented corporate culture form the heart of Evonik's corporate strategy. They are the lever for profitable growth and a sustained increase in the value of the company. Evonik benefits specifically from its customer proximity and leading market positions. Evonik is active in over 100 countries around the world. In fiscal 2018, the enterprise with more than 32,000 employees generated sales of EUR13.3 billion and an operating profit (adjusted EBITDA) of EUR2.15 billion from continuing operations.

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.

Tim Lange
Head of Investor Relations
Phone +49 201 177-3150

Evonik Industries AG
Rellinghauser Straße 1-11
45128 Essen
Phone +49 201 177-01
Fax +49 201 177-3475

Supervisory Board
Bernd Tönjes, Chairman
Executive Board
Christian Kullmann, Chairman
Dr. Harald Schwager, Deputy Chairman
Thomas Wessel, Ute Wolf

Registered Office is Essen
Register Court Essen Local Court
Commercial Registry B 19474

05.11.2019 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language: English
Company: Evonik Industries AG
Rellinghauser Straße 1-11
45128 Essen
Phone: +49 (0) 201 177-01
Fax: +49 (0) 201 177-3475
E-mail: investor-relations@evonik.com
Internet: www.evonik.com
Indices: MDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Luxembourg Stock Exchange
EQS News ID: 903797

End of News DGAP News Service

903797  05.11.2019 

© EQS 2019

share with twitter share with LinkedIn share with facebook
10/29EVONIK INDUSTRIES AG : quaterly earnings release
10/29EVONIK INDUSTRIES : and HP develop 3D-printable thermoplastic elastomer to enabl..
10/27EVONIK : JP Morgan reiterates its Buy rating
10/21EVONIK INDUSTRIES : sells stake in Synoste to Globus Medical in successful ventu..
10/19EVONIK : Independant Research gives a Buy rating
10/19EVONIK : NorldLB reiterates its Neutral rating
10/16EVONIK : UBS remains a Sell rating
10/16EVONIK : DZ Bank keeps its Buy rating
10/16EVONIK : Receives a Buy rating from JP Morgan
10/15EVONIK : Goldman Sachs reaffirms its Buy rating
More news
Sales 2020 12 245 M 14 259 M 14 259 M
Net income 2020 552 M 643 M 643 M
Net Debt 2020 3 206 M 3 733 M 3 733 M
P/E ratio 2020 17,3x
Yield 2020 5,56%
Capitalization 9 615 M 11 205 M 11 196 M
EV / Sales 2020 1,05x
EV / Sales 2021 1,01x
Nbr of Employees 32 621
Free-Float 41,1%
Duration : Period :
Evonik Industries AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EVONIK INDUSTRIES AG
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 26,84 €
Last Close Price 20,67 €
Spread / Highest target 59,7%
Spread / Average Target 29,8%
Spread / Lowest Target 1,60%
EPS Revisions
Christian Kullmann Chairman-Executive Board
Bernd Tönjes Chairman-Supervisory Board
Ute Wolf Chief Financial Officer
Andreas Fischer Chief Innovation Officer
Siegfried Luther Independent Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
BASF SE-30.11%50 382
DUPONT DE NEMOURS, INC.-11.40%42 534
ROYAL DSM N.V.18.39%27 162